menu
    • menu
    [{"orgOrder":0,"company":"Alector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AL101","moa":"Progranulin","graph1":"Neurology","graph2":"Phase I","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alector \/ Not Applicable"},{"orgOrder":0,"company":"Alector","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Anti-SIRP-alpha antibody","moa":"SIRP alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Alector \/ Alector","highestDevelopmentStatusID":"4","companyTruncated":"Alector \/ Alector"},{"orgOrder":0,"company":"Alector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AL002","moa":"TREM2","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ Not Applicable"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"AL001","moa":"Progranulin","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":2.2000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ GlaxoSmithKline","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Alector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AL001","moa":"Progranulin","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ Not Applicable"},{"orgOrder":0,"company":"Alector","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Termination","leadProduct":"AL003","moa":"CD33","graph1":"Neurology","graph2":"Phase I","graph3":"Alector","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.23000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Abbvie","highestDevelopmentStatusID":"6","companyTruncated":"Alector \/ Abbvie"},{"orgOrder":0,"company":"Alector","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AL002","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alector \/ AbbVie","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ AbbVie"},{"orgOrder":0,"company":"Alector","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Latozinemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Alector \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Alector","sponsor":"Cantor Fitzgerald & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Latozinemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Alector \/ Cantor Fitzgerald & Co","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ Cantor Fitzgerald & Co"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"GSK4527226","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Alector \/ GSK"},{"orgOrder":0,"company":"Alector","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Latozinemab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alector \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Alector \/ GSK"}]

    Find Clinical Drug Pipeline Developments & Deals by Alector

    Menu

    Alector

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Latozinemab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Cantor Fitzgerald & Co

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alector Announces Closing of Public Offering

                            Details : Proceeds will fund research, development, and manufacturing of AL001 (latozinemab), a progranulin modulator for frontotemporal dementia with progranulin mutation.

                            Brand Name : AL001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 19, 2024

                            Lead Product(s) : Latozinemab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Cantor Fitzgerald & Co

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GSK4527226

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial

                            Details : AL101 (GSK4527226) is an investigational monoclonal antibody targeting the sortilin receptor, developed for treating early Alzheimer’s disease, including mild cognitive impairment and dementia.

                            Brand Name : AL101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 08, 2024

                            Lead Product(s) : GSK4527226

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Latozinemab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Breakthrough Designation To Latozinemab for FTD-GRN

                            Details : AL001 (latozinemab) is an investigational monoclonal antibody designed to modulate progranulin, developed for treating frontotemporal dementia due to a progranulin gene mutation.

                            Brand Name : AL001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 07, 2024

                            Lead Product(s) : Latozinemab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Latozinemab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Cantor Fitzgerald & Co.

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alector Announces Pricing of Public Offering of Common Stock

                            Details : Proceeds will fund research, development, and manufacturing of AL001 (latozinemab), a progranulin modulator for frontotemporal dementia with progranulin mutation.

                            Brand Name : AL001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 17, 2024

                            Lead Product(s) : Latozinemab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Cantor Fitzgerald & Co.

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AL003

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $225.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            AbbVie Dumps An Early-Alzheimer's Candidate Developing In Collaboration With Alector

                            Details : The Company, in collaboration with AbbVie pursuant to the AbbVie Agreement, continues to develop the Company’s AL003 program, which is focused on targeting Triggering Receptor Expressed on Myeloid cells 2 (TREM2), for the treatment of Alzheimer’s dis...

                            Brand Name : AL003

                            Molecule Type : Large molecule

                            Upfront Cash : $205.0 million

                            June 30, 2022

                            Lead Product(s) : AL003

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $225.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AL001

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alector to Present New AL001 Data at AD/PD™ 2022

                            Details : AL001 is being studied in Phase 2 trial for the treatment of frontotemporal dementia patients with a C9orf72 mutation (FTD-C9orf72). FTD-C9orf72 is associated with abnormal accumulation of the protein TDP-43.

                            Brand Name : AL001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 08, 2022

                            Lead Product(s) : AL001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AL001

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : GSK

                            Deal Size : $2,200.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GSK and Alector Announce Global Collaboration in Immuno-Neurology for Two Clinical Stage Monoclonal Antibodies

                            Details : GSK and Alector to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease.

                            Brand Name : AL001

                            Molecule Type : Large molecule

                            Upfront Cash : $700.0 million

                            July 02, 2021

                            Lead Product(s) : AL001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : GSK

                            Deal Size : $2,200.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AL002

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheime...

                            Details : AL002 is an investigational humanized monoclonal antibody that targets triggering receptor expressed on myeloid cells 2 (TREM2) with the most important genetic links to sporadic Alzheimer’s disease.

                            Brand Name : AL002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 25, 2021

                            Lead Product(s) : AL002

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AL002

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002

                            Details : AL002 was shown to be well-tolerated in a first-in-human Phase 1 SAD study in healthy volunteers and modulated cerebrospinal fluid biomarkers indicative of brain target engagement.

                            Brand Name : AL002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 25, 2020

                            Lead Product(s) : AL002

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Alector

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anti-SIRP-alpha antibody

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antib...

                            Details : Under the agreement, Innovent will lead the development and commercialization of the molecule in China, including the manufacturing of the product.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 26, 2020

                            Lead Product(s) : Anti-SIRP-alpha antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth